Idh1 - isocitrate dehydrogenase 1 (NADP+), soluble Gene

Also Known as Id-1; Idpc; Idh-1; E030024J03Rik

Species: Mus musculus

Gene Type: protein coding
Gene ID: 15926

About Idh1

Chromosome 1: 65,197,775-65,225,659 reverse strand.GRCm39:CM000994.3

This gene has 7 transcripts (splice variants), 231 orthologues, 1 paralogue and is associated with 3 phenotypes. Ubiquitous expression in kidney adult (RPKM 14.), CNS E18 (RPKM 83.7) and 25 other tissues.

Summary

Enables isocitrate dehydrogenase (NADP+) activity. Acts upstream of or within glutathione metabolic process; regulation of phospholipid metabolic process; and response to oxidative stress. Located in cytosol and mitochondrion. Is expressed in several structures, including alimentary system; genitourinary system; integumental system; nervous system; and sensory organ. Human ortholog(s) of this gene implicated in autoimmune disease; hematologic Cancer (multiple); hepatocellular clear cell carcinoma; and high grade glioma (multiple). Orthologous to human IDH1 (isocitrate dehydrogenase (NADP(+)) 1). [provided by Alliance of Genome Resources, Apr 2022]

Idh1 Products (2)

mRNA Protein Name
NM_001111320.1 NP_001104790.1 isocitrate dehydrogenase [NADP] cytoplasmic
NM_010497.3 NP_034627.3 isocitrate dehydrogenase [NADP] cytoplasmic

Idh1 Protein Structure

PTZ00435

PTZ00435: PTZ00435 (0 - 410)

  • 0
  • 100
  • 200
  • 300
  • 414 a.a.
Protein Preferred Names Protein Names

isocitrate dehydrogenase [NADP] cytoplasmic

  • IDH

  • IDP

  • NADP(+)-specific ICDH

  • cytosolic NADP-isocitrate dehydrogenase

  • oxalosuccinate decarboxylase

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-18767 Ivosidenib Inhibitor 99.89% Yes
HY-104042 Vorasidenib Inhibitor 99.76% Yes
HY-114226 Olutasidenib Inhibitor 99.16% Yes

Clinical Phase

Bioactive Molecules (5)
Cat. No. Product Name Effect
Purity Phase
HY-145594 Safusidenib Inhibitor 99.05% Phase 3
HY-104036 IDH-305 Inhibitor 99.15% Phase 2
HY-100020 BAY-1436032 Inhibitor 99.79% Phase 1
HY-131312 Crelosidenib Inhibitor / Phase 1
HY-131312A Crelosidenib gentisate Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (19)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-18082 AGI-5198 Inhibitor 99.93% Unkown
HY-19540 GSK864 Inhibitor 99.91% Unkown
HY-128661 IDH1 Inhibitor 2 Inhibitor 98.70% Unkown
HY-112056 DIM-C-pPhCO2Me Inhibitor 99.29% Unkown
HY-128888 (R,R)-GSK321 Inhibitor 99.36% Unkown
HY-12475 Mutant IDH1-IN-1 Inhibitor 98.78% Unkown
HY-128888B (S,R)-GSK321 Control 98.62% Unkown
HY-18717 Mutant IDH1-IN-2 Inhibitor 98.50% Unkown
HY-150238 IDH1 Inhibitor 7 Inhibitor 99.46% Unkown
HY-110144 TC-E 5008 Inhibitor / Unkown
HY-123153 GSK990 Control / Unkown
HY-149359 IHMT-IDH1-053 Inhibitor / Unkown
HY-158319 Mutant IDH1/NAMPT-IN-1 Inhibitor / Unkown
HY-121916 ML309 Inhibitor / Unkown
HY-175213 Mutant IDH1-IN-7 Inhibitor / Unkown
HY-175770 mIDH1-IN-2 Inhibitor / Unkown
HY-120765 BRD2879 Inhibitor / Unkown
HY-100476 Mutant IDH1-IN-3 Inhibitor / Unkown
HY-162631 IDH1 Inhibitor 9 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Idh1 NCBI NCBI:3417